Health products policy and standards
Our team provides authoritative guidance and standards on quality, safety and efficacy of health products and supports countries to formulate evidence-based policies and ensure good practice throughout the value chain.
INN for Biosimilars
The general policies for assigning INNs to biologicals had been in place for
many years but the field was becoming more and more complex. Glycosylated and
non-glycosylated proteins posed different problems. Differences in
glycosylation had been handled by adding a Greek letter in full as a second
word. In view of the increasing complexity of this whole field, the WHO INN
Expert Group had requested the WHO INN Secretariat to prepare a working
document intended to summarize and review the past and present INN situation.
INN for Biosimilar Products